Table 4 Clinical course and outcome of COVID-19 patients without and with de novo bronchiectasis included in the study
From: Prevalence and early outcome of bronchiectasis as an atypical presentation in COVID-19 patients
COVID-19 without bronchiectasis (n = 400) | COVID-19 with de novo bronchiectasis (n = 14) | P | |
|---|---|---|---|
Management site | < 0.001 | ||
At home | 195 (48.8%) | 3 (21.4%) | |
At the ward | 104 (26%) | 2 (14.3%) | |
ICU | 101 (25.3%) | 9 (64.3%) | |
Hospital stay (day) | 4.33 ± 2.15 | 25.14 ± 10.98 | < 0.001 |
ICU’s stay (day) | 1.79 ± 1.32 | 11.07 ± 10.45 | < 0.001 |
Ventilatory support | |||
NRM | 73 (18.3%) | 2 (14.3%) | 0.51 |
Vapotherm | 25 (6.3%) | 1 (7.1%) | 0.61 |
Non-invasive ventilation | 81 (20.3%) | 7 (50%) | 0.01 |
Mechanical ventilation | 51 (12.8%) | 7 (50%) | < 0.001 |
Duration of MV (day) | 3.57 ± 1.23 | 14.13 ± 7.57 | < 0.001 |
Outcome | |||
Alive | 341 (85.3%) | 9 (64.3%) | 0.04 |
Death | 59 (14.8%) | 5 (35.7%) | |